
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


EDAP TMS SA (EDAP)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: EDAP (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $5.75
1 Year Target Price $5.75
0 | Strong Buy |
1 | Buy |
2 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.62% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.48M USD | Price to earnings Ratio - | 1Y Target Price 5.75 |
Price to earnings Ratio - | 1Y Target Price 5.75 | ||
Volume (30-day avg) 3 | Beta -0.09 | 52 Weeks Range 1.21 - 4.40 | Updated Date 08/15/2025 |
52 Weeks Range 1.21 - 4.40 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -34.33% | Operating Margin (TTM) -44.22% |
Management Effectiveness
Return on Assets (TTM) -16.54% | Return on Equity (TTM) -49.28% |
Valuation
Trailing PE - | Forward PE 38.02 | Enterprise Value 34378696 | Price to Sales(TTM) 0.8 |
Enterprise Value 34378696 | Price to Sales(TTM) 0.8 | ||
Enterprise Value to Revenue 0.47 | Enterprise Value to EBITDA 1165.78 | Shares Outstanding 37392100 | Shares Floating 29010276 |
Shares Outstanding 37392100 | Shares Floating 29010276 | ||
Percent Insiders - | Percent Institutions 40.19 |
Upturn AI SWOT
EDAP TMS SA

Company Overview
History and Background
EDAP TMS SA was founded in 1979 in France. It initially focused on developing and marketing medical devices for urology. Significant milestones include the development of focused ultrasound technologies for non-invasive treatment of various conditions and its public listing.
Core Business Areas
- High-Intensity Focused Ultrasound (HIFU): Develops, manufactures, and markets HIFU devices for the non-invasive ablation of tumors, primarily prostate cancer. Core products include the Focal One and Ablatherm HIFU systems.
- Extracorporeal Shockwave Lithotripsy (ESWL): Develops, manufactures, and markets ESWL devices for the non-invasive treatment of kidney stones. Core product is the Sonolith i-sys.
Leadership and Structure
The company is led by Marc Oczachowski, Chief Executive Officer. The organizational structure includes departments for R&D, manufacturing, sales, marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Focal One: A HIFU system for precise and personalized prostate cancer ablation. The estimated market share within the HIFU prostate cancer treatment market is approximately 25%. Competitors include Profound Medical (PROF), Sonacare Medical, and Exact Imaging.
- Ablatherm: A HIFU system used for prostate cancer ablation. While older than Focal One, it still holds a presence. Market share is declining relative to Focal One and competitor systems. Competitors are similar to Focal One: Profound Medical (PROF), Sonacare Medical.
- Sonolith i-sys: An ESWL system for treating kidney stones. The ESWL market is mature. Competitors include Siemens Healthineers (SIEGY), Dornier MedTech, and Olympus (OCPNY).
Market Dynamics
Industry Overview
The market for minimally invasive surgical and therapeutic devices is growing, driven by patient preference, technological advancements, and an aging population. The prostate cancer treatment market, in particular, is experiencing innovation in imaging and ablation technologies.
Positioning
EDAP TMS SA is positioned as a leader in HIFU technology for prostate cancer treatment. Its competitive advantages include its established brand, technological expertise, and clinical data supporting the efficacy of its HIFU systems.
Total Addressable Market (TAM)
The global prostate cancer diagnostics and treatment market is expected to reach $13.7 billion by 2028. EDAP TMS SA is positioned to capture a portion of this TAM through its HIFU technology, focusing on non-invasive ablation.
Upturn SWOT Analysis
Strengths
- Leading HIFU technology
- Established brand reputation
- Strong clinical data
- Global distribution network
Weaknesses
- Reliance on HIFU market
- Limited product diversification
- Geographic concentration in Europe
- Smaller company size relative to competitors
Opportunities
- Expanding HIFU applications
- Entering new geographic markets
- Developing partnerships with imaging companies
- Acquiring complementary technologies
Threats
- Competition from established medical device companies
- Technological advancements in alternative therapies
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- Profound Medical (PROF)
- Siemens Healthineers (SIEGY)
- Intuitive Surgical (ISRG)
Competitive Landscape
EDAP TMS SA competes with larger medical device companies. Its advantage lies in its specialized HIFU technology. Its disadvantages include its smaller size and limited product diversification.
Growth Trajectory and Initiatives
Historical Growth: EDAP TMS SA has experienced revenue growth in recent years, driven by increased adoption of HIFU technology. However, profitability has been inconsistent.
Future Projections: Analysts project continued revenue growth, driven by expanding HIFU applications and geographic expansion. Profitability is expected to improve with scale.
Recent Initiatives: Recent strategic initiatives include expanding sales and marketing efforts, investing in R&D, and pursuing regulatory approvals in new markets.
Summary
EDAP TMS SA is a company specializing in HIFU technology for prostate cancer treatment and ESWL for kidney stones. While being a leader in its niche market, it faces competition from larger players. Its strengths are its technology and brand, while weaknesses include limited diversification. Overall, the company has potential for growth, but needs to capitalize on the market opportunities to improve the bottom line.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Market Research Reports
- Analyst Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share estimates are approximate. Financial data is based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About EDAP TMS SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1997-07-31 | CEO & Director Mr. Ryan Rhodes | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 310 | Website https://focalone.com |
Full time employees 310 | Website https://focalone.com |
EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.